Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Psomri Holding AB is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is handled by 1 distinct examiner, YOO, SUN JAE, and is located in 1 distinct art unit. The busiest examiner for the portfolio is YOO, SUN JAE, who is responsible for 1 busiest examiner pending action. The portfolio's prosecution is currently concentrated under a single examiner and a single art unit.
For Psomri Holding AB, this indicates a very specific technical focus within the Biotechnology & Pharmaceuticals sector. The total of 1 pending office action matches the workload of the busiest examiner, YOO, SUN JAE, confirming that there is no distribution of pending cases across other examiners. This centralized structure suggests a direct prosecution path where the progress of the company's current patent efforts relies solely on the review and interpretation of a single examiner. While this simplifies the administrative burden, it also means that the company's immediate patent goals are tied to the specific examination style and technical standards of YOO, SUN JAE within a single art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOO, SUN JAE | 1 | 70.9% | +1.0% |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700978 | NEW SALT FORMS OF AMILORIDE AND ITS DERIVATIVES FOR PHARMACEUTICAL USE | YOO, SUN JAE | 1621 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPsomri Holding AB has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sun Jae Yoo has the most, with 1 of Psomri Holding AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.